Women’s Health Diagnostics Market Overview:
Global Women’s Health Diagnostics Market was valued at $13,133 million in 2016, and is projected to reach $21,501 million at a CAGR of 7.0% from 2017 to 2023. Women are more prone to certain diseases, mostly related to menstrual disorders, depression, osteoporosis, obesity, and autoimmune diseases. Women’s major health issues are related to the reproductive system that includes infertility, polycystic ovarian syndrome, menopause, and cancers such as breast cancer, cervical cancer, and urological disorders.
Rise in geriatric female population, increase in incidence of chronic and lifestyle disorders, demand for point of care diagnostic testing, and high adoption of diagnostics imaging procedures. Moreover, numerous government initiatives to promote women health awareness also drives the market growth. However, the market growth is limited by high cost of diagnostics tests and dearth of skilled professionals. Conversely, surge in demand for the development of miniature diagnostic devices, rise in healthcare infrastructure, and creative marketing initiatives by key vendors in emerging countries are expected to provide lucrative opportunities for the market expansion during the forecast period.
The global women’s health diagnostics market is segmented based on type, end user, and region. Based on type, the market is divided into diagnostic devices, diagnostic tests, and accessories and consumables. The devices segment is further segmented into biopsy devices and imaging and monitoring system. Imaging and monitoring systems segment is further segmented into ultrasound imaging systems, mammography systems, MRI systems, and nuclear imaging. Ultrasound imaging systems is further sub segmented into OB/GYN ultrasound and breast ultrasound. Mammography systems are further categorized as analog mammography systems, digital mammography systems, and breast tomosynthesis system. Tests segment is further categorized as breast cancer testing, cervical cancer testing, prenatal genetic screening and carrier testing, pregnancy and ovulation testing, and ovarian cancer testing.
Breast cancer testing is further segmented into hormone receptor test, immunohistochemistry test, and other tests. Cervical cancer testing is bifurcated into PAP smear and HPV test. Prenatal genetic screening and carrier testing include tests for cystic fibrosis and other diseases. The pregnancy and ovulation testing segment is further bifurcated into lab-based pregnancy and ovulation testing, and home-based pregnancy and ovulation testing. Depending on end user, it is categorized into hospitals and clinics, home care settings, diagnostic and imaging centers, and others. Based on region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Diagnostic tests segment accounted for the largest market share in 2016 and is expected to remain so throughout the forecast period. Diagnostic tests involve various tests related to women’s health such as pregnancy and ovulation tests, breast cancer tests, ovarian cancer tests, and others. Factors such as high adoption of point-of-care diagnostics, rise in prevalence of women’s health-related disorders, and growth in awareness about various tests drives the market for diagnostic tests. In addition, growth in healthcare expenditure, rise in awareness about malignant tumors, and availability of newer and advanced diagnostic systems further boost the market growth in near future.
Snapshot of LAMEA Women’s Health Diagnostics Market
Rise in focus of market vendors on emerging markets, namely, Asia-Pacific and LAMEA regions, is expected to boost the market growth. According to Institute for Health Metrics and Evaluation, the annual mortality rate per 100,000 people from ovarian cancer increases with an average rate of 3.7% a year. Moreover, the estimates of Census 2011 in South Africa reveal that around 2.5 million females in South Africa belonged to the age group of 60 years and above in 2011. Hence, these people are prone to encounter various chronic and lifestyle disorders. Thus, LAMEA offers a huge customer base to the manufacturers of women’s health diagnostics market.
The list of key players profiled in this report include Abbott Laboratories, Becton, Dickinson and Company, Carestream Health, F. Hoffmann-La Roche AG, GE Healthcare, Hologic, Inc., Koninklijke Philips N.V., Quest Diagnostics Inc., Cardinal Health, and Siemens AG.
Key players in the value chain include MedGyn Products, Inc., Cook Medical Incorporated, Thermo Fisher Scientific, and C. R. Bard, Inc.
Key Benefits for Stakeholders
- The study provides an in-depth analysis of the global women’s health diagnostics market with current trends and future estimations from 2016 to 2023 to elucidate the imminent investment pockets.
- Comprehensive analysis of factors that drive and restrict the market growth is provided.
- Identification of factors instrumental in changing the market scenario, rise in opportunities, and identification of key companies that can influence this market on a global & regional scale are provided.
- Key players are profiled and their strategies are analyzed thoroughly to understand the competitive outlook of the market.
Women’s Health Diagnostics Market Key Segments:
- Diagnostic Devices
- Biopsy Devices
- Imaging and Monitoring System
- Ultrasound Devices
- OB/GYN Ultrasound
- Breast Ultrasound
- Mammography Systems
- Analog Mammography
- Digital Mammography
- Breast Tomosynthesis
- MRI Systems
- Nuclear Imaging
- Ultrasound Devices
- Diagnostic Tests
- Breast Cancer Testing
- Hormone Receptor Test
- Immunohistochemistry (IHC) Test
- Other Tests
- Cervical Cancer Testing
- PAP Smear (PAP) Test
- HPV Test
- Prenatal Genetic Screening and Carrier Testing
- Cystic Fibrosis
- Other Diseases
- Pregnancy and Ovulation Testing
- Lab-based Pregnancy and Ovulation Testing
- Home Based Pregnancy and Ovulation Testing
- Ovarian Cancer Testing
- Breast Cancer Testing
- Accessories and Consumables
By End User
- Hospitals and Clinics
- Home Care Settings
- Diagnostic and Imaging Centers
- North America
- Rest of Europe
- South Korea
- Rest of Asia-Pacific
- Saudi Arabia
- South Africa
- Rest of LAMEA
FutureIndustryInsight™ provides quantified B2B research on 20,000 high growth emerging opportunities/threats which will impact 75% to 85% of worldwide companies’ revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 70,000 top officers across eight industries worldwide approach FutureIndustryInsight™ for their painpoints around revenues decisions.
Designation: Global Sales Manager